Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001798749-24-000059
Filing Date
2024-11-12
Accepted
2024-11-12 16:40:34
Documents
64
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20240930x10q.htm   iXBRL 10-Q 1868779
2 EX-10.1 tmb-20240930xex10d1.htm EX-10.1 217027
3 EX-31.1 tmb-20240930xex31d1.htm EX-31.1 9567
4 EX-31.2 tmb-20240930xex31d2.htm EX-31.2 9588
5 EX-32.1 tmb-20240930xex32d1.htm EX-32.1 5431
6 EX-32.2 tmb-20240930xex32d2.htm EX-32.2 5467
7 GRAPHIC tmb-20240930xex10d1001.jpg GRAPHIC 5693
  Complete submission text file 0001798749-24-000059.txt   7586398

Data Files

Seq Description Document Type Size
8 EX-101.SCH tmb-20240930.xsd EX-101.SCH 34841
9 EX-101.CAL tmb-20240930_cal.xml EX-101.CAL 49201
10 EX-101.DEF tmb-20240930_def.xml EX-101.DEF 129366
11 EX-101.LAB tmb-20240930_lab.xml EX-101.LAB 330367
12 EX-101.PRE tmb-20240930_pre.xml EX-101.PRE 260346
67 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20240930x10q_htm.xml XML 1511330
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40544 | Film No.: 241449177
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)